Real Clinical Practice in ALK-rearranged NSCLC Patients: A Retrospective Observational Study

Background/Aim: To describe real clinical outcomes when using systemic therapy to treat non-small cell lung cancer (NSCLC) patients who have anaplastic lymphoma kinase (ALK) fusion gene mutation. Patients and Methods: We performed a retrospective chart review from April 2008 to March 2019 sourced from 16 medical institutes that cover a population of three million people. Results: There were 129 ALK rearranged NSCLC patients. Among them, 103 patients including 40 recurrent disease cases received ALK-tyrosine kinase inhibitors (TKI) and chemotherapy. Our treatment results were comparable to previously reported clinical trials and clinical practice studies. First-line alectinib, treatment sequence of ALK-TKI followed by another ALK-TKI, and pemetrexed-containing chemotherapy contributed to the outcome of treatment. Conclusion: By arrangement of treatment such as treatment sequence of ALK-TKI and chemotherapy regimen, it might be possible to obtain a treatment outcome almost equivalent to those of clinical trials even in real clinical practice.

[1]  F. Cappuzzo,et al.  Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study , 2019, Clinical and Translational Oncology.

[2]  D. Planchard,et al.  Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study). , 2019, Lung cancer.

[3]  P. Xing,et al.  Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study , 2019, Cancer medicine.

[4]  G. Peters.  From ‘Targeted Therapy’ to Targeted Therapy* , 2019, AntiCancer Research.

[5]  N. Pavlakis,et al.  Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[6]  E. Imyanitov,et al.  Overall Survival of Patients With ALK-Positive Metastatic Non–Small-Cell Lung Cancer in the Russian Federation: Nationwide Cohort Study , 2019, Journal of global oncology.

[7]  M. Mishaeli,et al.  Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort , 2019, Oncology Research and Treatment.

[8]  Derek E. Smith,et al.  Natural History and Factors Associated with Overall Survival in Stage IV ALK‐Rearranged Non–Small Cell Lung Cancer , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  A. Gemma,et al.  Safety and effectiveness of alectinib in a real‐world surveillance study in patients with ALK‐positive non–small‐cell lung cancer in Japan , 2019, Cancer science.

[10]  Jorge E Gomez,et al.  Neoadjuvant Tyrosine Kinase Inhibition in Locally-advanced Non-small Cell Lung Cancer: Two Cases and a Brief Literature Review , 2019, AntiCancer Research.

[11]  K. Furukawa,et al.  Real Clinical Practice of Using Afatinib Therapy in NSCLC Patients with an Acquired EGFR T790M Mutation , 2018, AntiCancer Research.

[12]  B. Besse,et al.  Making the first move in EGFR-driven or ALK-driven NSCLC: first-generation or next-generation TKI? , 2018, Nature Reviews Clinical Oncology.

[13]  J. Black-Shinn,et al.  Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study , 2018, Journal of clinical medicine.

[14]  A. Cardona,et al.  Real-World Treatment Patterns, Survival, and Prediction of CNS Progression in ALK-Positive Non-Small-Cell Lung Cancer Patients Treated with First-Line Crizotinib in Latin America Oncology Practices , 2018, Oncology.

[15]  K. Davis,et al.  Real-world outcomes in patients with ALK-positive non-small cell lung cancer treated with crizotinib. , 2018, Current oncology.

[16]  M. Dibonaventura,et al.  Real-world usage and clinical outcomes of alectinib among post-crizotinib progression anaplastic lymphoma kinase positive non-small-cell lung cancer patients in the USA , 2017, OncoTargets and therapy.

[17]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[18]  D. Moro-Sibilot,et al.  Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study , 2017, Oncotarget.

[19]  E. Gabazza,et al.  Sequential Therapy with Crizotinib and Alectinib in ALK‐Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  B. Melosky,et al.  Treatment patterns and survival in patients with ALK-positive non-small-cell lung cancer: a Canadian retrospective study. , 2016, Current oncology.

[21]  H. Satoh,et al.  Response to pemetrexed rechallenge after acquired resistance of ALK inhibitors. , 2016, Lung cancer.

[22]  J. Kolesar,et al.  Role of anaplastic lymphoma kinase inhibition in the treatment of non-small-cell lung cancer. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[23]  J. Engelman,et al.  Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib , 2015, Clinical Cancer Research.

[24]  R. Palmer,et al.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology , 2013, Nature Reviews Cancer.

[25]  K. Furukawa,et al.  Observational study on the efficacy and safety of erlotinib in patients with non-small cell lung cancer , 2012, Oncology letters.

[26]  K. Furukawa,et al.  Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group , 2012, Medical Oncology.

[27]  Laura La Paglia,et al.  Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. , 2010, Cancer treatment reviews.

[28]  K. Furukawa,et al.  A population-based study of gefitinib in patients with non-small cell lung cancer , 2009, Medical oncology.